Eculizumab hypersensitivity and desensitization in a toddler with atypical hemolytic uremic syndrome

Lo, R.; Alexander, Steven R.; Moss, Jeff; Siddiqi, Aminaa; Liu, Anne

doi:10.1016/j.jaip.2019.03.027

Cited by 4 publications

(3 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Immediate hypersensitivity reactions or infusion reactions due to eculizumab are very rare 172,173 . A case of anaphylaxis diagnosed with STs was successfully desensitized with a rapid protocol 174 (Table 3).…”

Section: Anti‐cytokine/anti‐inflammatory Drugs Used For Mas/cytokine mentioning

confidence: 99%

Diagnosis and management of the drug hypersensitivity reactions in Coronavirus disease 19: An EAACI Position Paper

Gelincik

Brockow

Çelik

et al. 2020

Allergy

View full text Add to dashboard Cite

Coronavirus disease 2019 (COVID‐19), a respiratory tract infection caused by a novel human coronavirus, the severe acute respiratory syndrome coronavirus 2, leads to a wide spectrum of clinical manifestations ranging from asymptomatic cases to patients with mild and severe symptoms, with or without pneumonia. Given the huge influence caused by the overwhelming COVID‐19 pandemic affecting over three million people worldwide, a wide spectrum of drugs is considered for the treatment in the concept of repurposing and off‐label use. There is no knowledge about the diagnosis and clinical management of the drug hypersensitivity reactions that can potentially occur during the disease. This review brings together all the published information about the diagnosis and management of drug hypersensitivity reactions due to current and candidate off‐label drugs and highlights relevant recommendations. Furthermore, it gathers all the dermatologic manifestations reported during the disease for guiding the clinicians to establish a better differential diagnosis of drug hypersensitivity reactions in the course of the disease.

show abstract

Section: Anti‐cytokine/anti‐inflammatory Drugs Used For Mas/cytokine mentioning

confidence: 99%

Diagnosis and management of the drug hypersensitivity reactions in Coronavirus disease 19: An EAACI Position Paper

Gelincik

Brockow

Çelik

et al. 2020

Allergy

View full text Add to dashboard Cite

show abstract

“…Hypersensitivity was reported during only two out of 84 desensitizations, and one of them required adrenaline administration [50]. In addition to previously described mAbs, successful desensitizations have been reported for alemtuzumab, denosumab, eculizumab, and natalizumab [53][54][55][56][57].…”

Section: Desensitizationmentioning

confidence: 99%

Hypersensitivity Reactions to Biologicals: from Bench to Bedside

Akarsu

Soyer

2020

Curr Treat Options Allergy

View full text Add to dashboard Cite

Purpose of Review Biologic agents are new treatment options for chronic inflammatory diseases and cancers. As a result of their unique mechanism of action, they are more effective and less toxic treatment option and their clinical usage is increasing. While they are more commonly used, various adverse effects have been observed including lifethreatening ones, including anaphylaxis. The aim of this review is to distinguish the anaphylaxis from other hypersensitivity reactions (HSR) and provide a management algorithm for the anaphylactic reactions induced by biological agents. Recent Findings Many case reports and series have been published regarding anaphylaxis and other hypersensitivity reactions (concerning cytokine release syndrome, acute infusion-related reactions) due to biologic agents. Although acute treatment of HSR varies according to the clinical presentation, desensitization with the drug is the major management option for subsequent administrations in the case of anaphylactic reactions. Summary Anaphylaxis and other immediate onset hypersensitivity reactions are occasionally difficult to differentiate from each other, and mixed-type reactions may be observed. Immediate management of anaphylaxis includes discontinuation of infusion, immediate administration of adrenaline, antihistamines, corticosteroids, and other treatment options depending on the symptoms. After 30-120 min of the reaction, a blood sample for serum tryptase levels should be obtained and after 4-6 weeks skin testing with the culprit drug should be performed for decision of long-term management via either graded challenge or desensitization.

show abstract

“…IHRs or infusion reactions due to eculizumab are very rare (169,170). A case of anaphylaxis diagnosed with STs was sucessfully desensitized with a rapid protocol (171).…”

Section: Hypersensitivity Reactionsmentioning

confidence: 99%

Diagnosis and management of the drug hypersensitivity reactions in Coronavirus disease 19

Gelincik

Brockow

Çelik

et al. 2020

Preprint

View full text Add to dashboard Cite

Coronavirus disease 2019 (COVID-19), a respiratory tract infection caused by a novel human coronavirus, the severe acute respiratory syndrome coronavirus 2, leads to a wide spectrum of clinical manifestations ranging from asymptomatic cases to patients with mild and severe symptoms, with or without pneumonia. Given the huge influence caused by the overwhelming COVID-19 pandemic affecting over three million people worldwide, a wide spectrum of drugs is considered for the treatment in the concept of repurposing and off-label use. There is no knowledge about the diagnosis and clinical management of the drug hypersensitivity reactions that can potentially occur during the disease. This review brings together all the published information about the diagnosis and management of drug hypersensitivity reactions due to current and candidate off-label drugs and highlights relevant recommendations. Furthermore, it gathers all the dermatologic manifestations reported during the disease for guiding the clinicians to establish a better differential diagnosis of drug hypersensitivity reactions in the course of the disease.

show abstract

Eculizumab hypersensitivity and desensitization in a toddler with atypical hemolytic uremic syndrome

Cited by 4 publications

References 7 publications

Diagnosis and management of the drug hypersensitivity reactions in Coronavirus disease 19: An EAACI Position Paper

Diagnosis and management of the drug hypersensitivity reactions in Coronavirus disease 19: An EAACI Position Paper

Hypersensitivity Reactions to Biologicals: from Bench to Bedside

Diagnosis and management of the drug hypersensitivity reactions in Coronavirus disease 19

Contact Info

Product

Resources

About